Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Conditions

• SCLC,Extensive Stage

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• RYZ101 Dose Level 1 — DRUG
  Dose Level 1
• RYZ101 Dose Level 2 — DRUG
  Dose Level 2
• RYZ101 Dose Level 3 — DRUG
  Dose Level 3
• RYZ101 Dose Level -1 — DRUG
  Dose Level -1
• Atezolizumab — DRUG
  Atezolizumab
• Carboplatin — DRUG
  Carboplatin
• Etoposide — DRUG
  Etoposide

Study Details

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

Key Dates

Start date

Oct 10, 2022

Status verified

Apr 2026

Primary completion

Jul 31, 2027

Completion

Jul 31, 2027

Study Design

Enrollment

21 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: RYZ101 + SoC

Primary Outcome Measure

RP2D [ Time Frame: 42 days of study treatment ]

Locations (12)

Find similar trials in Los Angeles, CA